Seillier Célia, Lesec Léonie, Hélie Pauline, Marie Charlotte, Vivien Denis, Docagne Fabian, Le Mauff Brigitte, Toutirais Olivier
Institut Blood and Brain @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Normandie Univ, UNICAEN, INSERM, GIP Cyceron, Caen, France.
Present address: Theodor Kocher Institute, University of Bern, Freiestrasse 1, CH-3012, Bern, Switzerland.
J Inflamm (Lond). 2024 Feb 14;21(1):4. doi: 10.1186/s12950-024-00375-0.
Tissue-plasminogen activator (tPA) is a serine protease well known for its fibrinolytic function. Recent studies indicate that tPA could also modulate inflammation via plasmin generation and/or by receptor mediated signalling in vitro. However, the contribution of tPA in inflammatory processes in vivo has not been fully addressed. Therefore, using tPA-deficient mice, we have analysed the effect of lipopolysaccharide (LPS) challenge on the phenotype of myeloid cells including neutrophils, macrophages and dendritic cells (DCs) in spleen. We found that LPS treatment upregulated the frequency of major histocompatibility class two (MHCII) macrophages but also, paradoxically, induced a deep downregulation of MHCII molecule level on macrophages and on conventional dendritic cells 2 (cDC2). Expression level of the CD11b integrin, known as a tPA receptor, was upregulated by LPS on MHCII macrophages and cDC2, suggesting that tPA effects could be amplified during inflammation. In tPA mice under inflammatory conditions, expression of costimulatory CD86 molecules on MHCII macrophages was decreased compared to WT mice, while in steady state the expression of MHCII molecules was higher on macrophages. Finally, we reported that tPA deficiency slightly modified the phenotype of DCs and T cells in acute inflammatory conditions. Overall, our findings indicate that in vivo, LPS injection had an unexpectedly bimodal effect on MHCII expression on macrophages and DCs that consequently might affect adaptive immunity. tPA could also participate in the regulation of the T cell response by modulating the levels of CD86 and MHCII molecules on macrophages.
组织型纤溶酶原激活剂(tPA)是一种以其纤溶功能而闻名的丝氨酸蛋白酶。最近的研究表明,tPA在体外也可通过纤溶酶生成和/或受体介导的信号传导来调节炎症。然而,tPA在体内炎症过程中的作用尚未得到充分研究。因此,我们使用tPA缺陷小鼠,分析了脂多糖(LPS)刺激对脾脏中包括中性粒细胞、巨噬细胞和树突状细胞(DC)在内的髓样细胞表型的影响。我们发现,LPS处理上调了主要组织相容性复合体II类(MHCII)巨噬细胞的频率,但矛盾的是,它也导致巨噬细胞和传统树突状细胞2(cDC2)上MHCII分子水平的深度下调。作为tPA受体的CD11b整合素的表达水平在LPS作用下,在MHCII巨噬细胞和cDC2上上调,这表明在炎症过程中tPA的作用可能会被放大。在炎症条件下的tPA基因敲除小鼠中,与野生型小鼠相比,MHCII巨噬细胞上共刺激分子CD86的表达降低,而在稳态下,巨噬细胞上MHCII分子的表达更高。最后,我们报道在急性炎症条件下,tPA缺陷对DC和T细胞的表型有轻微影响。总体而言,我们的研究结果表明,在体内,LPS注射对巨噬细胞和DC上的MHCII表达产生了意想不到的双峰效应,这可能会影响适应性免疫。tPA还可能通过调节巨噬细胞上CD86和MHCII分子的水平参与T细胞反应的调节。